719 related articles for article (PubMed ID: 20361178)
21. Pancreastatin inhibitor PSTi8 protects the obesity associated skeletal muscle insulin resistance in diet induced streptozotocin-treated diabetic mice.
Gupta AP; Garg R; Singh P; Goand UK; Syed AA; Valicherla GR; Riyazuddin M; Mugale MN; Gayen JR
Eur J Pharmacol; 2020 Aug; 881():173204. PubMed ID: 32439261
[TBL] [Abstract][Full Text] [Related]
22. Dysfunctional fat cells, lipotoxicity and type 2 diabetes.
DeFronzo RA
Int J Clin Pract Suppl; 2004 Oct; (143):9-21. PubMed ID: 16035392
[TBL] [Abstract][Full Text] [Related]
23. Lipogenesis in arterial wall and vascular smooth muscular cells: regulation and abnormalities in insulin-resistance.
Hamlat N; Forcheron F; Negazzi S; del Carmine P; Feugier P; Bricca G; Aouichat-Bouguerra S; Beylot M
Cardiovasc Diabetol; 2009 Dec; 8():64. PubMed ID: 20030821
[TBL] [Abstract][Full Text] [Related]
24. Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones.
Smith SA
Biochimie; 2003 Dec; 85(12):1219-30. PubMed ID: 14739074
[TBL] [Abstract][Full Text] [Related]
25. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes.
Hagberg CE; Mehlem A; Falkevall A; Muhl L; Fam BC; Ortsäter H; Scotney P; Nyqvist D; Samén E; Lu L; Stone-Elander S; Proietto J; Andrikopoulos S; Sjöholm A; Nash A; Eriksson U
Nature; 2012 Oct; 490(7420):426-30. PubMed ID: 23023133
[TBL] [Abstract][Full Text] [Related]
26. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids.
Smith U; Kahn BB
J Intern Med; 2016 Nov; 280(5):465-475. PubMed ID: 27699898
[TBL] [Abstract][Full Text] [Related]
27. [Adiponectin: from adipocyte to skeletal muscle].
Ferré P
Ann Endocrinol (Paris); 2004 Feb; 65(1 Suppl):S36-43. PubMed ID: 15163922
[TBL] [Abstract][Full Text] [Related]
28. Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones.
Del Prato S; Marchetti P
Diabetes Technol Ther; 2004 Oct; 6(5):719-31. PubMed ID: 15628822
[TBL] [Abstract][Full Text] [Related]
29. Insulin resistance and its impact on the approach to therapy of type 2 diabetes.
Laakso M
Int J Clin Pract Suppl; 2001 Sep; (121):8-12. PubMed ID: 11594246
[TBL] [Abstract][Full Text] [Related]
30. The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity.
Kraegen EW; Cooney GJ; Ye JM; Thompson AL; Furler SM
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S189-201. PubMed ID: 11460570
[TBL] [Abstract][Full Text] [Related]
31. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
32. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
33. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.
Walter H; Lübben G
Drugs; 2005; 65(1):1-13. PubMed ID: 15610048
[TBL] [Abstract][Full Text] [Related]
34. Role of skeletal muscle lipids in the pathogenesis of insulin resistance of obesity and type 2 diabetes.
Gilbert M
J Diabetes Investig; 2021 Nov; 12(11):1934-1941. PubMed ID: 34132491
[TBL] [Abstract][Full Text] [Related]
35. Targeting ceramide metabolism in obesity.
Aburasayn H; Al Batran R; Ussher JR
Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E423-35. PubMed ID: 27382035
[TBL] [Abstract][Full Text] [Related]
36. Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes.
Dandona P; Ghanim H; Chaudhuri A; Mohanty P
J Diabetes Complications; 2008; 22(1):62-75. PubMed ID: 18191079
[TBL] [Abstract][Full Text] [Related]
37. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Henry RR
Clin Ther; 2003; 25 Suppl B():B47-63. PubMed ID: 14553866
[TBL] [Abstract][Full Text] [Related]
38. [Metabolic abnormalities as a basis for age-dependent diseases and aging? State of the art].
Tereshina EV
Adv Gerontol; 2009; 22(1):129-38. PubMed ID: 19827683
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities.
Beckman J; Raji A; Plutzky J
Curr Opin Cardiol; 2003 Nov; 18(6):479-85. PubMed ID: 14597889
[TBL] [Abstract][Full Text] [Related]
40. Fatty acid-induced mitochondrial uncoupling in adipocytes as a key protective factor against insulin resistance and beta cell dysfunction: a new concept in the pathogenesis of obesity-associated type 2 diabetes mellitus.
Maassen JA; Romijn JA; Heine RJ
Diabetologia; 2007 Oct; 50(10):2036-41. PubMed ID: 17712547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
